

Project 2 - Liver Angiotensinogen Promotes Renal Scarring

Project Leader: **Iekuni Ichikawa, M.D., Ph.D.**

Co-Investigator: Ji Ma, M.D., Ph.D.

Consultant: Taiji Matsusaka, M.D., Ph.D.

Keywords: renal scarring angiotensinogen

[Expand](#)

Inhibition of angiotensin II (All) is the only therapy currently known to have some effect in chronic kidney disease (CKD). However, current ways of inhibiting only attenuate, but do not halt, progression. Our studies aim to find new ways to inhibit All in the kidney by determining why kidney All is activated in CKD. We will use mice with absence of All precursor in the liver or kidney, and mice that cannot reabsorb the precursor molecule because of a tubular defect, to determine why All is increased and how it can be blocked.